Imugene Ltd
ASX:IMU
Intrinsic Value
Imugene Ltd. is a biopharmaceutical company, which engages in the research, development, and commercialisation of health technologies against cancer. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of IMU.
Imugene Ltd's market capitalization is 509m AUD.
IMU stock price is 0.071 AUD.
IMU.
IMU. Open DCF Valuation
IMU. Open Relative Valuation
IMU has upside potential of 384% compared to the average analyst price target.
Open Wall St Estimates
IMU has negative Free Cash Flow for the last twelve months.
IMU has negative Operating Income for the last twelve months.
IMU has negative Net Income for the last twelve months.
IMU's ROE (Return on Equity) has significantly decreased in the last 3 years from -18% to -44%, and is approaching profitability.
IMU's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from -38% to -135%, and is approaching profitability.
IMU's ROE (Return on Equity) for the past 12 months is negative and is equal to -44%.
IMU's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -135%.
IMU's D/E (Debt to Equity) is very low and is equal to 0.02.
IMU has negative three-year average ROE (Return on Equity): -29%. The company is not efficient at transforming stockholders' equity into net income.
IMU has negative three-year average ROIC (Return on Invested Capital): -82%. The company is not efficient at using invested capital to generate operating income.
IMU's short-term assets (168m AUD) exceed its short-term liabilties (29m AUD).
IMU's long-term assets (230m AUD) exceed its long-term liabilties (36m AUD).
IMU has negative Net Debt. This means that the company has more cash and short-term investments (139m AUD) than debt (4m AUD).
IMU's Altman Z-Score is very high and is equal to 10.89.
Fundamental Analysis
Imugene Ltd
Balance Sheet Decomposition
Imugene Ltd
| Current Assets | 167.7m |
| Cash & Short-Term Investments | 139.4m |
| Receivables | 20.4m |
| Other Current Assets | 7.9m |
| Non-Current Assets | 62.7m |
| Long-Term Investments | 217.6k |
| PP&E | 23.3m |
| Intangibles | 38.3m |
| Other Non-Current Assets | 936.3k |
| Current Liabilities | 29.3m |
| Accounts Payable | 3.6m |
| Accrued Liabilities | 4.6m |
| Other Current Liabilities | 21m |
| Non-Current Liabilities | 6.3m |
| Long-Term Debt | 4.2m |
| Other Non-Current Liabilities | 2.2m |
Earnings Waterfall
Imugene Ltd
|
Revenue
|
0
AUD
|
|
Operating Expenses
|
-92.9m
AUD
|
|
Operating Income
|
-92.9m
AUD
|
|
Other Expenses
|
3.7m
AUD
|
|
Net Income
|
-89.2m
AUD
|
Free Cash Flow Analysis
Imugene Ltd
What is Free Cash Flow?
IMU Profitability Score
Profitability Due Diligence
Imugene Ltd's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
Score
Imugene Ltd's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
IMU Solvency Score
Solvency Due Diligence
Imugene Ltd's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Score
Imugene Ltd's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
IMU Price Targets Summary
Imugene Ltd
According to Wall Street analysts, the average 1-year price target for
IMU
is 0.343 AUD
with a low forecast of 0.101 AUD and a high forecast of 0.515 AUD.
Shareholder Return
IMU Price
Imugene Ltd
| Average Annual Return | 139.78% |
| Standard Deviation of Annual Returns | 173.88% |
| Max Drawdown | -93% |
| Market Capitalization | 509m AUD |
| Shares Outstanding | 7 393 820 160 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Imugene Ltd
Country
Industry
Market Cap
Dividend Yield
Description
Imugene Ltd. is a biopharmaceutical company, which engages in the research, development, and commercialisation of health technologies against cancer. The company is headquartered in Sydney, New South Wales. The firm is engaged in developing immunotherapies that seeks to activate the immune system of cancer patients to treat and eradicate tumors. Its platform technology seeks to harness the body’s immune system against cancerous tumors. Its product pipeline includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with care drugs and immunotherapies such as chimeric antigen receptor T cells (CAR T’s) for solid tumors. Its PD-1 B-cell immunotherapy, known as PD1-Vaxx, aims to induce the body to produce polyclonal antibodies that block PD-1 signaling, and thus produce an anticancer effect similar to Keytruda, Opdivo and the other immune checkpoint inhibitor monoclonal antibodies for the treatment of cancers. Its clinical trial candidates include VAXinia (CF33 + hNIS), CHECKvacc (CF33 + hNIS + PD-L1), B-Vaxx and others.
You don't have any saved screeners yet
